Liquidity has deteriorated significantly, with the current ratio falling to 0.85 in 2026Q1, indicating that current liabilities now exceed the company's $3.9 million cash balance.
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 |
|---|
| Total Current Assets | 4.21M | 7.67M | 5.77M | 4.87M | 2.38M | 6.11M | 10.23M | 718K | 314.14K | 1.23M | 2.02M | 1.71M | 6.05M | 2.48M | 624.88K | 1.99M |
| Cash & Short-Term Investments | 3.93M | 7.38M | 5.62M | 4.49M | 2.31M | 6.06M | 9.82M | 419K | 97.08K | 53.78K | 148.84K | 608.7K | 5.83M | 2.39M | 543.41K | 1.9M |
| Cash Only | 3.93M | 7.38M | 5.62M | 4.49M | 2.31M | 6.06M | 9.82M | 419K | 97.08K | 53.78K | 148.84K | 608.7K | 5.83M | 2.39M | 543.41K | 1.9M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 66K | 70K | 22.78K | 121.78K | 92.06K | 18.45K | 23.25K | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | 122.84 | 191.19 | 75.41 | 54.93 | 47.03 | 141.97 | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 284K | 184K | 171K | 957.35K | 1.42M | 816.22K | 83.65K | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 285K | 284K | 151K | 376K | 67K | 43K | 56K | 21.71K | 9.7K | 63.82K | 266.43K | 211.59K | 67.75K | 93.05K | 81.47K | 92.82K |
| Total Non-Current Assets | 142K | 171K | 164K | 37K | 59K | 160K | 377K | 378K | 374.04K | 441.88K | 443.45K | 420.5K | 299.96K | 277.24K | 189.69K | 193.18K |
| Property, Plant & Equipment | 142K | 171K | 154K | 27K | 40K | 109K | 315K | 321K | 149.78K | 216.75K | 240.45K | 220.46K | 122.49K | 107.21K | 70.2K | 82.87K |
| Fixed Asset Turnover | 0.00x | - | - | - | - | - | - | 0.65x | 0.29x | 2.72x | 2.54x | 0.65x | 0.49x | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 10K | 0 | 15K | 51K | 0 | 0 | 52.6K | 39.56K | 35.67K | 35.15K | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 10K | 4K | 0 | 62K | 57K | 171.66K | 185.57K | 167.33K | 164.88K | 177.47K | 170.03K | 119.49K | 110.31K |
| Total Assets | 4.36M | 7.84M | 5.93M | 4.91M | 2.44M | 6.26M | 10.61M | 1.1M | 688.19K | 1.67M | 2.46M | 2.13M | 6.35M | 2.76M | 814.57K | 2.18M |
| Asset Turnover | 0.00x | - | - | - | - | - | - | 0.19x | 0.06x | 0.35x | 0.25x | 0.07x | 0.01x | - | - | - |
| Asset Growth % | 2460.36% | 32.13% | 20.94% | 101.19% | -61.09% | -40.93% | 867.7% | 59.26% | -58.76% | -32.18% | 15.39% | -66.41% | 130.33% | 238.36% | -62.68% | - |
| Total Current Liabilities | 4.97M | 4.77M | 1.27M | 1.51M | 1.01M | 883K | 1.34M | 2.27M | 3.22M | 3.69M | 2.35M | 1.51M | 1M | 310.91K | 457.95K | 283.04K |
| Accounts Payable | 1.3M | 1.32M | 992K | 839K | 672K | 631K | 869K | 1.53M | 2.06M | 2.42M | 1.63M | 1.08M | 104.71K | 49.79K | 122.54K | 71.76K |
| Days Payables Outstanding | 28.91K | - | - | - | - | - | - | - | - | - | - | - | - | 290.83 | 940.79K | - |
| Short-Term Debt | 26K | 28K | 5K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 454.53K | 0 | 37.43K | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 3.65M | 3.43M | 252K | 673K | 341K | 98K | 244K | 195K | 239.96K | 336.78K | 363.74K | 240.36K | 204.89K | 261.12K | 297.99K | 211.28K |
| Current Ratio | 0.85x | 1.61x | 4.52x | 3.22x | 2.35x | 6.91x | 7.61x | 0.32x | 0.10x | 0.33x | 0.86x | 1.13x | 6.05x | 7.97x | 1.36x | 7.03x |
| Quick Ratio | 0.85x | 1.61x | 4.52x | 3.22x | 2.35x | 6.91x | 7.39x | 0.24x | 0.04x | 0.07x | 0.25x | 0.59x | 5.96x | 7.97x | 1.36x | 7.03x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 232K | 237K | 17.66M | 196K | 195K | 227K | 279K | 236K | 339.88K | 14.56M | 11.06M | 7.59M | 10.18M | 13.51M | 859.69K | 931.22K |
| Long-Term Debt | 0 | 5K | 203K | 196K | 195K | 210K | 197K | 191K | 168.22K | 182.77K | 162.03K | 160.31K | 163.46K | 693.09K | 630.58K | 606.14K |
| Capital Lease Obligations | 19K | 0 | 33K | 0 | 0 | 17K | 82K | 45K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 232K | 232K | 17.42M | 0 | 0 | 0 | 0 | 0 | 171.66K | 14.38M | 10.9M | 7.43M | 10.02M | 8.45M | 229.11K | 325.07K |
| Total Liabilities | 5.21M | 5.01M | 18.93M | 1.71M | 1.21M | 1.11M | 1.62M | 2.51M | 3.56M | 18.24M | 13.41M | 9.1M | 11.18M | 13.82M | 1.32M | 1.21M |
| Total Debt | 26K | 33K | 267K | 196K | 195K | 250K | 363K | 378K | 168.22K | 182.77K | 162.03K | 160.31K | 617.99K | 693.09K | 37.43K | 606.14K |
| Net Debt | -3.9M | -7.35M | -5.35M | -4.3M | -2.12M | -5.81M | -9.46M | -41K | 71.14K | 128.99K | 13.2K | -448.39K | -5.21M | -1.69M | -505.98K | -1.29M |
| Debt / Equity | -0.03x | 0.01x | - | 0.06x | 0.16x | 0.05x | 0.04x | - | - | - | - | - | - | - | - | 0.63x |
| Debt / EBITDA | -0.00x | - | - | - | - | - | - | 0.11x | 0.03x | 0.02x | 0.03x | 0.03x | 0.17x | 0.23x | 0.01x | - |
| Net Debt / EBITDA | 0.48x | - | - | - | - | - | - | -0.01x | 0.01x | 0.01x | 0.00x | -0.10x | -1.43x | -0.55x | -0.18x | - |
| Interest Coverage | -136.22x | - | -34.98x | - | -1477.33x | - | - | -350.60x | -366.16x | -422.38x | -332.60x | -383.23x | -0.55x | -172.12x | -417.24x | -75.38x |
| Total Equity | -851K | 2.83M | -13M | 3.2M | 1.23M | 5.16M | 8.98M | -1.41M | -2.87M | -16.57M | -10.95M | -6.97M | -4.83M | -11.06M | -503.07K | 968.24K |
| Equity Growth % | 487.61% | 121.75% | -506.63% | 159.92% | -76.14% | -42.61% | 736.12% | 50.86% | 82.66% | -51.38% | -57.07% | -44.26% | 56.32% | -2099.13% | -151.96% | - |
| Book Value per Share | -0.52 | 3.14 | -34.95 | 15.40 | 7.95 | 33.36 | 59.57 | -11.85 | - | -2.43 | -1.82 | -1.23 | -0.91 | -135.02 | -1230.51 | 2.47 |
| Total Shareholders' Equity | -851K | 2.83M | -13M | 3.2M | 1.23M | 5.16M | 8.98M | -1.41M | -2.87M | -16.57M | -10.95M | -6.97M | -4.83M | -11.06M | -503.07K | 968.24K |
| Common Stock | 3K | 1K | 1K | 20K | 15K | 15K | 15K | 162K | 141.64K | 6.82K | 6.03K | 5.69K | 5.32K | 5.3K | 5.46K | 5.3K |
| Retained Earnings | -156.17M | -151.84M | -132.45M | -109.85M | -101.9M | -97.47M | -93.4M | -90.7M | -87.19M | -47.37M | -35.6M | -29.38M | -23.09M | -25.65M | -15.29M | -12.52M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 44K | 41K | -8K | 64K | 17K | -6K | 15K | 124K | 164.23K | 110.67K | 62.58K | 90.17K | 66.67K | 52.7K | 8.93K | 22.63K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital sustainability and dilution
As reported in financial statements, GlucoTrack's total assets have contracted from $10.2 million in 2025Q2 to $4.4 million by 2026Q1, reflecting a persistent depletion of resources that underscores the company's precarious financial trajectory as it attempts to fund its pivot toward an implantable device platform.
The consistent decline in total assets suggests that the company is consuming its capital base faster than it can replenish it through financing activities. This trend warrants close monitoring, as the shrinking asset base limits the firm's operational flexibility and increases the urgency for a successful regulatory milestone.
Based on recent SEC filings, the company's current ratio has deteriorated significantly, falling from 3.27 in 2025Q2 to 0.85 in 2026Q1, which indicates that current liabilities now exceed current assets and highlights a tightening liquidity position that may necessitate immediate external capital intervention to maintain operations.
A current ratio below 1.0 is a concerning indicator for a pre-revenue entity, as it suggests that the company may struggle to meet its short-term obligations without further dilution. Investors should interpret this as a sign that the firm's cash runway is likely insufficient to support its current R&D burn rate.
According to the company's reported figures, shareholders' equity has swung from a positive $2.8 million in 2025Q4 to a negative $851,000 in 2026Q1, a shift driven by the accumulation of $156.2 million in retained losses that effectively wipes out the firm's book value.
The transition to negative equity suggests that the company is operating in a state of technical insolvency, relying entirely on external financing to cover its ongoing losses. This structure implies that any future value for shareholders is entirely contingent on the successful commercialization of its new technology.
As indicated by the provided financial data, the company's asset base is almost entirely devoid of tangible productive assets, with net PPE of only $142,000, suggesting that the firm's value is tied exclusively to intangible intellectual property that remains unproven in a commercial clinical setting.
The lack of significant tangible assets means that in a liquidation scenario, there is virtually no recovery value for investors. This composition highlights that the balance sheet is highly sensitive to impairment risks if the current R&D efforts fail to yield a viable, regulatory-approved medical device.
Quick answers to the most common questions about buying GCTK stock.
As of 2025, GlucoTrack, Inc. (GCTK) had total assets of $7.8M including $7.7M in current assets.
GlucoTrack, Inc. (GCTK) carries total debt of $0.0M, offset by $7.4M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
GlucoTrack, Inc. (GCTK) has total shareholders' equity (book value) of $2.8M ($3.14 book value per share). Book value represents the net worth of the company belonging to common stock holders.
GlucoTrack, Inc. (GCTK) reported a current ratio of 1.61x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.